 MONTREAL, Feb. 04, 2021 GLOBE NEWSWIRE -- Theratechnologies Inc. Theratechnologies TSX: TH NASDAQ: THTX, a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration FDA has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy. 